Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...
Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...
JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...
IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...
Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...
Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...
Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...
NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs
The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying...
Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...
WuXi STA Breaks Ground on New US Manufacturing Site in Delaware
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...
Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...
Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...
Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...
Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...
Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...